Keyword: Samsung Bioepis

Samsung BioLogics has faced scrutiny of a biosimilars joint venture. Now, officials are looking more closely into the company's 2016 public listing.

Biologics CDMO Samsung BioLogics has kept up its frantic growth even as it deals with legal issues tied to its joint venture with Biogen.

The European exodus from branded Humira to biosimilars confirms that AbbVie was was way too optimistic about sales erosion, a Bernstein report reveals.

A court has suspended penalties imposed on Samsung BioLogics by South Korea's accounting regulator while prosecutors investigate.

Samsung is fighting back against charges that it improperly changed the method by which it valued a joint venture with Biogen.

Korean securities watchdog has requested to review whether the company should be delisted and recommended the dismissal of its CEO.

China fines vaccine scandal-hit Changsheng $1.3 billion; Merck and Samsung bail on a Lantus biosim; Taiho grows VC fund to sixfold.

Merck canceled its partnership with Samsung Bioepis for a Lantus biosimilar after facing hurdles with pricing and production costs.

A Takeda founder descendant blasts the Shire deal, as the company moves its U.S. HQ closer to Shire; Sanofi revamps two global units.

Roche is battling competition from Herceptin biosimilars and has reportedly sued Bioepis over its biosimilar as it heads for the finish line.